Sp1 transcription factor as a target for anthracyclines: Effects on gene transcription

Biochimie

Volumn 90, Issue 7, 2008, Pages 976-987

  Mansilla, Sylvia ^a   Portugal, José ^a  

^a INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

Author keywords

Daunorubicin; Jurkat T lymphocytes; Sp1 DNA interactions; Transcription; WP631

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; TRANSCRIPTION FACTOR SP1; TRANSCRIPTOME;

CELL LINE; DNA PROTEIN COMPLEX; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IN VITRO STUDY; REVIEW; TIME;

ANTHRACYCLINES; CELL LINE, TUMOR; CELL-FREE SYSTEM; DAUNORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR STRUCTURE; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 45849085448     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2007.12.008     Document Type: Review

References (68)

1. Minotti G., Menna P., Salvatorelli E., Cairo G., and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56 (2004) 185-229
2. Chaires J.B. Molecular recognition of DNA by daunorubicin. In: Hurley L., and Chaires J.B. (Eds). Advances in DNA sequence Specific Agents (1996), JAI Press Inc., Greenwich, CT 141-167
3. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57 (1999) 727-741
4. Priebe W., Fokt I., Przewloka T., Chaires J.B., Portugal J., and Trent J.O. Exploiting anthracycline scaffold for designing DNA-targeting agents. Methods Enzymol. 340 (2001) 529-555
5. Frederick C.A., Williams L.D., Ughetto G., van der Marel G.A., van Boom J.H., Rich A., and Wang A.H. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 29 (1990) 2538-2549
6. Leng F., Priebe W., and Chaires J.B. Ultratight DNA binding of a new bisintercalating anthracycline antibiotic. Biochemistry 37 (1998) 1743-1753
7. Chaires J.B., Leng F.F., Przewloka T., Fokt I., Ling Y.H., Perez-Soler R., and Priebe W. Structure-based design of a new bisintercalating anthracycline antibiotic. J. Med. Chem. 40 (1997) 261-266
8. Portugal J., Martín B., Vaquero A., Ferrer N., Villamarín S., and Priebe W. Analysis of the effects of daunorubicin and WP631 on transcription. Curr. Med. Chem. 8 (2001) 1-8
9. Chaires J.B. Drug-DNA interactions. Curr. Opin. Struct. Biol. 8 (1998) 314-320
10. Portugal J., Cashman D.J., Trent J.O., Ferrer-Miralles N., Przewloka T., Fokt I., Priebe W., and Chaires J.B. A new bisintercalating anthracycline with picomolar DNA binding affinity. J. Med. Chem. 48 (2005) 8209-8219
11. Martín B., Vaquero A., Priebe W., and Portugal J. Bisanthracycline WP631 inhibits basal and Sp1-activated transcription initiation in vitro. Nucleic Acids Res. 27 (1999) 3402-3409
12. Villamarín S., Mansilla S., Ferrer-Miralles N., Priebe W., and Portugal J. A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631. Eur. J. Biochem. 270 (2003) 764-770
13. Mansilla S., Rojas M., Bataller M., Priebe W., and Portugal J. Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells. Biochem. Pharmacol. 73 (2007) 934-942
14. Hu G.G., Shui X., Leng F., Priebe W., Chaires J.B., and Williams L.D. Structure of a DNA-bisdaunomycin complex. Biochemistry 36 (1997) 5940-5946
15. Mansilla S., Bataller M., and Portugal J. Mitotic catastrophe as a consequence of chemotherapy. Anticancer Agents Med. Chem. 6 (2006) 589-602
16. Zunino F., Di Marco A., Zaccara A., and Luoni G. The inhibition of RNA polymerase by daunomycin. Chem. Biol. Interact 9 (1974) 25-36
17. Gniazdowski M., Denny W.A., Nelson S.M., and Czyz M. Effects of anticancer drugs on transcription factor-DNA interactions. Expert Opin. Ther. Targets 9 (2005) 471-489
18. Moro S., Beretta G.L., Dal Ben D., Nitiss J., Palumbo M., and Capranico G. Interaction model for anthracycline activity against DNA Topoisomerase II. Biochemistry 43 (2004) 7503-7513
19. Hurley L.H. DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer 2 (2002) 188-200
20. Bellorini M., Moncollin V., D'Incalci M., Mongelli N., and Mantovani R. Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription. Nucleic Acids Res. 23 (1995) 1657-1663
21. Vaquero A., and Portugal J. Modulation of DNA-protein interactions in the P1 and P2 c-myc promoters by two intercalating drugs. Eur. J. Biochem. 251 (1998) 435-442
22. Chiang S.-Y., Azizkhan J.C., and Beerman T.A. A comparison of DNA-binding drugs as inhibitors of E2F1- and Sp1-DNA complexes and associated gene expression. Biochemistry 37 (1998) 3109-3115
23. Blume S.W., Snyder R.C., Ray R., Thomas S., Koller C.A., and Miller D.M. Mithramycin inhibits Sp1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J. Clin. Invest. 88 (1991) 1613-1621
24. Gottesfeld J.M., Turner J.M., and Dervan P.B. Chemical approaches to control gene expression. Gene Expr. 9 (2000) 77-91
25. Bartkowiak J., Kapuscinski J., Melamed M.R., and Darzynkiewicz Z. Selective displacement of nuclear proteins by antitumor drugs having affinity for nucleic acids. Proc. Natl. Acad. Sci. USA 86 (1989) 5151-5154
26. Gniazdowski M., Denny W.A., Nelson S.M., and Czyz M. Transcription factors as targets for DNA-interacting drugs. Curr. Med. Chem. 10 (2003) 909-924
27. Thomas M.C., and Chiang C.M. The general transcription machinery and general cofactors. Crit. Rev. Biochem. Mol. Biol. 41 (2006) 105-178
28. Kadonaga J.T., Jones K.A., and Tjian R. Promoter-specific activation of RNA polymerase II transcription by Sp1. Trends Biochem. Sci. 11 (1986) 20-23
29. Nicolás M., Noé V., and Ciudad C.J. Transcriptional regulation of the human Sp1 gene promoter by the specificity protein (Sp) family members nuclear factor Y (NF-Y) and E2F. Biochem. J. 371 (2003) 265-275
30. Mansilla S., and Portugal J. Occurrence of DNA sequences specifically recognized by drugs in human promoters. J. Biomol. Struct. Dyn. 19 (2002) 669-679
31. Suske G. The Sp-family of transcription factors. Gene 238 (1999) 291-300
32. Safe S., and Abdelrahim M. Sp transcription factor family and its role in cancer. Eur. J. Cancer 41 (2005) 2438-2448
33. Udvadia A.J., Rogers K.T., Higgins P.D., Murata Y., Martin K.H., Humphrey P.A., and Horowitz J.M. Sp-1 binds promoter elements regulated by the RB protein and Sp-1-mediated transcription is stimulated by RB coexpression. Proc. Natl. Acad. Sci. USA 90 (1993) 3265-3269
34. Kennett S.B., Udvadia A.J., and Horowitz J.M. Sp3 encodes multiple proteins that differ in their capacity to stimulate or repress transcription. Nucleic Acids Res. 25 (1997) 3110-3117
35. Bernués J., Simmen K.A., Lewis J.D., Gunderson S.I., Polycarpou-Schwarz M., Moncollin V., Egly J.M., and Mattaj I.W. Common and unique transcription factor requirements of human U1 and U6 snRNA genes. EMBO J 12 (1993) 3573-3585
36. Robinson H., Priebe W., Chaires J.B., and Wang A.H.J. Binding of two novel bisdaunorubicins to DNA studied by NMR spectroscopy. Biochemistry 36 (1997) 8663-8670
37. Fox K.R., Webster R., Phelps R.J., Fokt I., and Priebe W. Sequence selective binding of bis-daunorubicin WP631 to DNA. Eur. J. Biochem. 271 (2004) 3556-3566
38. Botella L.M., Sánchez-Elsner T., Rius C., Corbi A., and Bernabéu C. Identification of a critical Sp1 site within the endoglin promoter and its involvement in the transforming growth factor-β stimulation. J. Biol. Chem. 276 (2001) 34486-34494
39. Villamarín S., Ferrer-Miralles N., Mansilla S., Priebe W., and Portugal J. Induction of G2/M arrest and inhibition of c-myc and p53 transcription by WP631 in Jurkat T cells. Biochem. Pharmacol. 63 (2002) 1251-1258
40. Inge T.H., Casson L.K., Priebe W., Trent J.O., Georgeson K.E., Miller D.M., and Bates P.J. Importance of Sp1 consensus motifs in the MYCN promoter. Surgery 132 (2002) 232-238
41. Mansilla S., Priebe W., and Portugal J. Sp1-targeted inhibition of gene transcription by WP631 in transfected lymphocytes. Biochemistry 43 (2004) 7584-7592
42. Nair R.R., Wang H., Jamaluddin M.S., Fokt I., Priebe W., and Boyd D.D. A bisanthracycline (WP631) represses uPAR gene expression and cell migration of RKO colon cancer cells by interfering with transcription factor binding to a chromatin-accessible -148/-124 promoter region. Oncol. Res. 15 (2005) 265-279
43. Sjøttem E., Andersen C., and Johansen T. Structural and functional analyses of DNA bending induced by Sp1 family transcription factors. J. Mol. Biol. 267 (1997) 490-504
44. Marco E., García-Nieto R., and Gago F. Assessment by molecular dynamics simulations of the structural determinants of DNA-binding specificity for transcription factor Sp1. J. Mol. Biol. 328 (2003) 9-32
45. Miller T.L., Jin Y., Sun J.M., Coutts A.S., Murphy L.C., and Davie J.R. Analysis of human breast cancer nuclear proteins binding to the promoter elements of the c-myc gene. J. Cell. Biochem. 60 (1996) 560-571
46. Tuck S.P., and Crawford L. Characterization of the human p53 gene promoter. Mol. Cell Biol. 9 (1989) 2163-2172
47. Fandos C., Sánchez-Feutrie M., Santalucía T., Viñals F., Cadefau J., Gumà A., Cussó R., Kaliman P., Canicio J., Palacín M., and Zorzano A. GLUT1 glucose transporter gene transcription is repressed by Sp3. Evidence for a regulatory role of Sp3 during myogenesis. J. Mol. Biol. 294 (1999) 103-119
48. Estévez R., Camps M., Rojas A.M., Testar X., Deves R., Hediger M.A., Zorzano A., and Palacín M. The amino acid transport system y+L/4F2hc is a heteromultimeric complex. FASEB J. 12 (1998) 1319-1329
49. Gaidarova S., and Jiménez S.A. Inhibition of basal and transforming growth factor-β-induced stimulation of COL1A1 transcription by the DNA intercalators, mitoxantrone and WP631, in cultured human dermal fibroblasts. J. Biol. Chem. 277 (2002) 38737-38745
50. Qureshi H.Y., Sylvester J., Mabrouk M.E., and Zafarullah M. TGF-β-induced expression of tissue inhibitor of metalloproteinases-3 gene in chondrocytes is mediated by extracellular signal-regulated kinase pathway and Sp1 transcription factor. J. Cell. Physiol. 203 (2005) 345-352
51. Moreno-Aliaga M.J., Swarbrick M.M., Lorente-Cebrián S., Stanhope K.L., Havel P.J., and Martínez J.A. Sp1-mediated transcription is involved in the induction of leptin by insulin-stimulated glucose metabolism. J. Mol. Endocrinol. 38 (2007) 537-546
52. Roninson I.B., Broude E.V., and Chang B.-D. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist. Updat. 4 (2001) 303-313
53. Scherf U., Ross D.T., Waltham M., Smith L.H., Lee J.K., Tanabe L., Kohn K.W., Reinhold W.C., Myers T.G., Andrews D.T., Scudiero D.A., Eisen M.B., Sausville E.A., Pommier Y., Botstein D., Brown P.O., and Weinstein J.N. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24 (2000) 236-244
54. Chang B.-D., Swift M.E., Shen M., Fang J., Broude E.V., and Roninson I.B. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc. Natl. Acad. Sci. USA 99 (2002) 389-394
55. Kudoh K., Ramanna M., Ravatn R., Elkahloun A.G., Bittner M.L., Meltzer P.S., Trent J.M., Dalton W.S., and Chin K.V. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60 (2000) 4161-4166
56. Mansilla S., Piña B., and Portugal J. Daunorubicin-induced variations in gene transcription: commitment to proliferation arrest, senescence and apoptosis. Biochem. J. 372 (2003) 703-711
57. Mansilla S., Priebe W., and Portugal J. Transcriptional changes facilitate miototic catastrophe in tumour cells that contain functional p53. Eur. J. Pharmacol. 540 (2006) 34-45
58. Elmore L.W., Rehder C.W., Di X., McChesney P.A., Jackson-Cook C.K., Gewirtz D.A., and Holt S.E. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J. Biol. Chem. 277 (2002) 35509-35515
59. Kikuchi A. Regulation of β-catenin signaling in the Wnt pathway. Biochem. Biophys. Res. Commun. 268 (2000) 243-248
60. Shay J.W., and Roninson I.B. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23 (2004) 2919-2933
61. Schmitt C.A. Cellular senescence and cancer treatment. Biochim. Biophys. Acta 1775 (2007) 5-20
62. Mansilla S., Priebe W., and Portugal J. Mitotic catastrophe results in cell death by caspase-dependent and caspase-independent mechanisms. Cell Cycle 5 (2006) 53-60
63. Duan S., Bleibel W.K., Huang R.S., Shukla S.J., Wu X., Badner J.A., and Dolan M.E. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res. 67 (2007) 5425-5433
64. Broude E.V., Demidenko Z.N., Vivo C., Swift M.E., Davis B.M., Blagosklonny M.V., and Roninson I.B. p21 (CDKN1A) is a negative regulator of p53 stability. Cell Cycle 6 (2007) 1468-1471
65. Williams A.O., Isaacs R.J., and Stowell K.M. Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions. BMC Mol. Biol. 8 (2007) 36
66. Marín S., Mansilla S., Garcia-Reyero N., Rojas M., Portugal J., and Piña B. Promoter-specific inhibition of transcription by daunorubicin in Saccharomyces cerevisiae. Biochem. J. 368 (2002) 131-136
67. Thorn J.T., Todd A.V., Warrilow D., Watt F., Molloy P.L., and Iland H.J. Characterization of the human N-ras promoter region. Oncogene 6 (1991) 1843-1850
68. Brooks A.R., Shiffman D., Chan C.S., Brooks E.E., and Milner P.G. Functional analysis of the human cyclin D2 and cyclin D3 promoters. J. Biol. Chem. 271 (1996) 9090-9099